B-M S and Otsuka launch Abilify Discmelt
US drugmaker Bristol-Myers Squibb and Japan's Otsuka Pharmaceutical have announced the launch of an orally disintegrating tablet version of their co-developed antipsychotic Abilify (arpiprazol), known as Abilify Discmelt. This follows the US Food and Drug Administration approval of the product in June this year.
The firms explained that the product, which is a vanilla flavored tablet, available in 10mg and 15mg dosages, was designed as a convenient alternative for schizophrenic patients, or those experiencing manic episodes associated with bipolar I disorder, who have difficulty swallowing tablets. Additionally, the drug is appropriate for the treatment of individuals who refuse to take the pills as prescribed, or those who pretend to take them.
The company's share price rose $0.22 to $21.20 in morning trading on the New York Stock Exchange on the day of the announcement.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze